Xiaomi Shares Jump on Europe EV Expansion Plan 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
Trump Signs Order to Cut Routine Childhood Vaccines 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Brazil Court Suspends Sigma Lithium Mine Operations 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Milei Threatens Falkland Oil Firms With Sanctions 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Nvidia CEO Says AGI Has Arrived With OpenAI GPT-6 Astra 
Add as a preferred source on Google
Prescriptions for GLP-1 weight-loss drugs among U.S. children under age 12 have surged more than 300-fold since 2019, as doctors increasingly turn to the medications to treat severe childhood obesity, according to a new study.
The research, published Friday in the journal Pediatrics, examined more than 3.5 million children between eight and 11 years old who had obesity but did not have diabetes. Researchers found that GLP-1 prescriptions increased from just 0.03% in 2019 to 9.3% as of June.
GLP-1 medications are not currently approved for weight loss in children younger than 12. However, clinical guidelines allow doctors to prescribe the drugs for obesity in children as young as eight in certain circumstances.
Most young patients receiving the treatments had significant health concerns. About 94% had severe obesity, while roughly 65% had at least one obesity-related condition, including high cholesterol, high blood pressure or sleep apnea.
A total of 20,282 children received GLP-1 medications during the study period. Novo Nordisk’s Wegovy was the most commonly prescribed drug, while doctors also used the company’s Saxenda and Eli Lilly’s Zepbound.
Lead researcher Dr. Babak Orandi, an obesity medicine specialist at NYU Langone Health, said the overall number of children under 12 receiving GLP-1 drugs remains relatively small. However, the rapid increase highlights growing interest in the medications as a childhood obesity treatment. Orandi said continued monitoring is necessary to assess their long-term safety and effectiveness in younger patients.
The study also identified potential disparities in access. Children living in higher-income communities were 55% more likely to receive GLP-1 prescriptions, raising concerns that cost, insurance coverage and access to pediatric specialists could limit availability for lower-income families.
Researchers analyzed data from Epic Cosmos, a national electronic health records database covering more than 300 million U.S. patients. Epic was not involved in conducting the study.
